Mesoblast Limited vs Annaly Capital Management, Inc. — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Annaly Capital Management, Inc. trades at $23.2 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 7.9× Mesoblast Limited's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NLY | |
|---|---|---|
Market Cap | $2.21B | $17.44B |
Sector | Technology | Financials |
52-Week High | $20.96 | $24.40 |
52-Week Low | $12.88 | $20.21 |
Enterprise Value | $2.21B | — |
Dividend Yield | — | 12.96% |
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →